Active-specific immunization against melanoma: Is the problem at the receiving end?

Seminars in Cancer Biology

Volumn 13, Issue 6, 2003, Pages 473-480

  Monsurrò, Vladia ^a   Wang, Ena ^a   Panelli, Monica C ^a   Nagorsen, Dirk ^a   Jin, Ping ^a   Katia, Zavaglia ^a   Smith, Kina ^a   Ngalame, Yvonne ^a   Even, Jos ^a   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Immunization; Immunotherapy; Interleukin 2; Melanoma

Indexed keywords

CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 100[209-217]; INTERLEUKIN 2; MELANOMA VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; EFFECTOR CELL; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; MELANOMA; MICROENVIRONMENT; PHYSIOLOGY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR CELL; TUMOR IMMUNOLOGY; TUMOR REGRESSION;

EID: 10744224733     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2003.09.011     Document Type: Article

References (66)

1. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B.et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643-1647.
2. Parmiani G., Colombo M.P. Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. Melanoma. Res. 5:1995;295-301.
3. Parmiani G., Castelli C., Dalerba P., Mortarini R., Rivoltini L., Marincola F.M.et al. Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going? J. Natl. Cancer Inst. 94:2002;805-818.
4. Boon T., Cerottini J.-C., Van den Eynde B., van der Bruggen P., Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:1994;337-365.
5. Rosenberg S.A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today. 18:1997;175-182.
6. Old L.J., Chen Y.T. New Paths in Human Cancer Serology. J. Exp. Med. 187:1998;1163-1167.
7. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3:2002;999-1005.
8. Marincola F.M., Wang E., Herlyn M., Seliger B., Ferrone S. Tumors as elusive targets of T cell-directed immunotherapy. Trends Immunol. 24:2003;334-341.
9. Lee K.-H., Wang E., Nielsen M.-B., Wunderlich J., Migueles S., Connors M.et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163:1999;6292-6300.
10. Pittet M.J., Speiser D.E., Lienard D., Valmori D., Guillaume P., Dutoit V.et al. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin. Cancer Res. 7:2001;796s-803s.
11. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H.et al. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1999;1669-1678.
12. Scheibenbogen C., Schmittel A., Keilholz U., Allgauer T., Hofmann U., Max R.et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J. Immunother. 23:2000;275-281.
13. Zimmerman P.A., Steiner L.L., Titanji V.P., Nde P.N., Bradley J.E., Pogonka T.et al. Three new DPB1 alleles identified in a Bantu-speaking population from central Cameroon. Tissue Antigens. 47:1996;293-299.
14. Kaech S.M., Hemby S., Kersh E., Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell. 111:2002;837-851.
15. Wherry E.J., Teichgraber V., Becker T.C., Masopust D., Kaech S.M., Antia R.et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4:2003;225-234.
16. Matzinger P. Danger model of immunity. Scand. J. Immunol. 54:2001;2-3.
17. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3:2002;991-998.
18. Natali P.G., Nicotra M.R., Bigotti A., Venturo I., Marcenaro L., Giacomini P.et al. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc. Natl. Acad Sci. USA. 86:1989;6719-6723.
19. Marincola F.M., Jaffe E.M., Hicklin D.J., Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74:2000;181-273.
20. Jager E., Ringhoffer M., Altmannsberger M., Arand M., Karbach J., Jager D.et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer. 71:1997;142-147.
21. Seliger B., Maeurer M.J., Ferrone S. TAP off - Tumors on. Immunol. Today. 18:1997;292-299.
22. Seliger B., Maeurer M.J., Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today. 21:2000;455-464.
23. Ohnmacht G.A., Wang E., Mocellin S., Abati A., Filie A., Fetsch P.A.et al. Short term kinetics of tumor antigen expression in response to vaccination. J. Immunol. 167:2001;1809-1820.
24. Kammula U.S., Lee K.-H., Riker A., Wang E., Ohnmacht G.A., Rosenberg S.A.et al. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J. Immunol. 163:1999;6867-6879.
25. Panelli M.C., Riker A., Kammula U.S., Lee K.-H., Wang E., Rosenberg S.A.et al. Expansion of tumor/T cell pairs from fine needle aspirates (FNA) of melanoma metastases. J. Immunol. 164:2000;495-504.
26. Tan L.C., Gudgeon N., Annels N.E., Hansasuta P., O'Callaghan C.A., Rowland-Jones S.et al. A re-evaluation of the frequency of CD8(+) T cells specific for EBV in healthy virus carriers. J. Immunol. 162:1999;1827-1835.
27. Appay V., Dunbar P.R., Callan M., Klenerman P., Gillespie G.M.A., Papagno L.et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8:2002;379-385.
28. Haque T., Taylor C., Wilkie G.M., Murad P., Amlot P.L., Beath S.et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation. 72:2001;1399-1402.
29. Rooney C.M., Roskrow M.A., Smith C.A., Brenner M.K., Heslop H.E. Immunotherapy of Epstein-Barr virus-associated cancer. J. Natl. Cancer Institut. Monogr. 23:1998;89-93.
30. Yamano Y., Nagai M., Brennan M., Mora C.A., Soldan S.S., Tomaru U.et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load. Blood. 99:2002;88-94.
31. Perez-Diez A., Spiess P.J., Restifo N.P., Matzinger P., Marincola F.M. Intensity of the vaccine-elicited immune response determines tumor clearence. J. Immunol. 168:2002;338-347.
32. Monsurrò V., Nielsen M.-B., Perez-Diez A., Dudley M.E., Wang E., Rosenberg S.A.et al. Kinetics of TCR use in response to repeated epitope-specific immunization. J. Immunol. 166:2001;5817-5825.
33. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S.et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:1999;677-685.
34. Speiser D.E., Colonna M., Ayyoub M., Cella M., Pittet M.J., Batard P.et al. The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells. J. Immunol. 167:2001;6165-6170.
35. Nielsen M.-B., Monsurro' V., Miguelse S., Wang E., Perez-Diez A., Lee K.-H.et al. Status of activation of circulating vaccine-elicited CD8+ T cells. J. Immunol. 165:2000;2287-2296.
36. Pittet M.J., Zippelius A., Speiser D.E., Assenmacher M., Guillaume P., Valmori D.et al. Ex vivo IFN-γ secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J. Immunol. 166:2001;7634-7640.
37. Appay V., Nixon D.F., Donahoe S.M., Gillespie G.M., Dong T., King A.et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192:2000;63-75.
38. Hamann D., Baars P.A., Rep M.H.G., Hoolbrink B., Kerkhof-Garde S.R., Klein M.R.et al. Phenotype and functional separation of memory and effector human CD8+ T cells. J. Exp. Med. 186:1997;1407-1418.
39. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:1999;659-660.
40. Champagne P., Ogg G.S., King A., Knabenhans C., Ellefsen K., Nobile M.et al. Skewed maturation of memory HIV-specific CD8 T lymphoctes. Nature. 410:2001;106-111.
41. Monsurro' V., Nagorsen D., Wang E., Provenzano M., Dudley M.E., Rosenberg S.A.et al. Functional heterogeneity of vaccine-induced CD8+ T cells. J. Immunol. 168:2002;5933-5942.
42. Migueles S.A., Laborico A.C., Shupert W.L., Sabbaghian M.S., Rabin R., Hallahan C.W.et al. HIV-specific CD8+ T cell proliferation is coupled to perforing expression and is maintained in nonprogressors. Nat. Immunol. 3:2002;1061-1068.
43. van Baarle D., Kostense S., van Oers M.H.J., Miedema F. Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol. 23:2002;586-591.
44. Speiser D.E., Lienard D., Pittet M.J., Batard P., Rimoldi D., Guillaume P.et al. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur. J. Immunol. 32:2002;731-741.
45. Marincola F.M. Interleukin-2. Biol. Ther. Cancer Updates. 4(3):1994;1-16.
46. Rosenberg S.A., Lotze M.T., Yang J.C., Aebersold P.M., Linehan W.M., Seipp C.A., White D.E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210:1989;474-484.
47. Boon T., Coulie P.G., Van den Eynde B. Tumor antigens recognized by T cells. Immunol. Today. 18:1997;267-268.
48. Cormier J.N., Salgaller M.L., Prevette T., Barracchini K.C., Rivoltini L., Restifo N.P.et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A [see comments]. Cancer J. Sci. Am. 3:1997;37-44.
49. Rosenberg S.A., Yang J.C., Schwartzentruber D., Hwu P., Marincola F.M., Topalian S.L.et al. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:1998;321-327.
50. Zinkernagel R.M. The role of antigen in maintaining T cell memory. Dev. Biol. Stand. 82:1994;189-191.
51. McMichael A., Hanke T. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat. Immunol. 2:2002;283-291.
52. Schluns K.S., Lefrancois L. Cytokine control of memory T-cell development and survival. Nat. Immunol. 3:2003;269-279.
53. DePaola F., Ridolfi R., Riccobon A., Flamini E., Barzanti F., Granato A.M.et al. Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2. Br. J. Cancer. 88:2003;320-326.
54. Pockaj B.A., Sherry R.M., Wei J.P., Yannelli J.R., Carter C.S., Leitman S.F.et al. Localization of 111 indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer. 73:1994;1731-1737.
55. Panelli MC, Wang E, Phan G, Puhlman M, Miller L, Ohnmacht GA, Klein H, Marincola FM. Genetic profiling of peripharal mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration. Genome Biol 2002;3 [RESEARCH0035].
56. Panelli MC, Martin B, Nagorsen D, Wang E, Smith K, Monsurro' V, Marincola FM. A genomic and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization. J Invest Dermatol, in press.
57. Sarwal, M. Gene expression profiling of allograft rejection using cDNA microarrays. In: Proceedings of the 27th Annual Meeting of American Society for Histocompatibility and Immunogenetics, 2001 January 1.
58. Sarwal M., Chang S., Barry C., Alizadeh A.A., Salvatierra O., Brown P.O. Genomic analysis of renal allograft dysfunction using cDNA microarrays. Transplant Proc. 33:2001;297-298.
59. Wang E., Marincola F.M. A natural history of melanoma: serial gene expression analysis. Immunol. Today. 21:2000;619-623.
60. Wang E., Miller L.D., Ohnmacht G.A., Mocellin S., Petersen D., Zhao Y.et al. Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 62:2002;3581-3586.
61. Wang E, Panelli MC, Marincola FM. Genomic analysis of cancer. Princ Pract Oncol, in press.
62. Howell W.M., Turner S.J., Bateman A.C., Theaker J.M. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun. 2:2001;25-31.
63. Howell W.M., Bateman A.C., Turner S.J., Collins A., Theaker J.M. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun. 3:2002;229-232.
64. Wang E, Adams S, Zhao Y, Panelli MC, Simon R, Klein H, Marincola FM. A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides. J Transl Med, 1: 4.
65. Marincola F.M. Translational medicine: a two way road. J. Transl. Med. 1:2003;1.
66. Wang E., Miller L., Ohnmacht G.A., Liu E., Marincola F.M. High fidelity mRNA amplification for gene profiling using cDNA microarrays. Nat. Biotech. 17:2000;457-459.